{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:23:08Z","timestamp":1790659388582,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02254-3","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:35:00Z","timestamp":1772609700000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chidamide combined with fulvestrant in the treatment of HR-positive, HER2-negative advanced breast cancer after failure of previous endocrine therapy: a single-arm, single-center, phase 2 study"],"prefix":"10.1186","volume":"28","clinical-trial-number":[{"clinical-trial-number":"chictr2100044282","registry":"10.18810\/chictr"}],"author":[{"given":"La","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ti","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"2254_CR1","first-page":"7","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"2254_CR2","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1634\/theoncologist.2014-0002","volume":"19","author":"M Bonotto","year":"2014","unstructured":"Bonotto M, Gerratana L, Poletto E, Driol P, Giangreco M, Russo S, et al. Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist. 2014;19:608\u201315.","journal-title":"Oncologist"},{"key":"2254_CR3","first-page":"299","volume":"14","author":"N Garmpis","year":"2017","unstructured":"Garmpis N, Damaskos C, Garmpi A, Kalampokas E, Kalampokas T, Spartalis E, et al. histone deacetylases as new therapeutic targets in triple-negative breast cancer: progress and promises. Cancer Genomics Proteomics. 2017;14:299\u2013313.","journal-title":"Cancer Genomics Proteomics"},{"key":"2254_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10911-012-9263-3","volume":"17","author":"R Connolly","year":"2012","unstructured":"Connolly R, Stearns V. Epigenetics as a therapeutic target in breast cancer. J Mammary Gland Biol Neoplasia. 2012;17:191\u2013204.","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"2254_CR5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10549-008-0148-5","volume":"117","author":"Q Zhou","year":"2009","unstructured":"Zhou Q, Shaw PG, Davidson NE. Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells. Breast Cancer Res Treat. 2009;117:443\u201351.","journal-title":"Breast Cancer Res Treat"},{"key":"2254_CR6","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41591-024-02813-1","volume":"30","author":"F Wang","year":"2024","unstructured":"Wang F, Jin Y, Wang M, Luo H-Y, Fang W-J, Wang Y-N, et al. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS\/pMMR colorectal cancer: a randomized phase 2 trial. Nat Med. 2024;30:1035\u201343.","journal-title":"Nat Med"},{"key":"2254_CR7","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/S1470-2045(19)30164-0","volume":"20","author":"Z Jiang","year":"2019","unstructured":"Jiang Z, Li W, Hu X, Zhang Q, Sun T, Cui S, et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:806\u201315.","journal-title":"Lancet Oncol"},{"key":"2254_CR8","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","volume":"69","author":"Z-Q Ning","year":"2012","unstructured":"Ning Z-Q, Li Z-B, Newman MJ, Shan S, Wang X-H, Pan D-S, et al. Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 2012;69:901\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2254_CR9","doi-asserted-by":"publisher","first-page":"948","DOI":"10.4161\/onci.20306","volume":"1","author":"L Shen","year":"2012","unstructured":"Shen L, Pili R. Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy. Oncoimmunology. 2012;1:948\u201350.","journal-title":"Oncoimmunology"},{"key":"2254_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s11033-016-4005-z","volume":"43","author":"S-H Lin","year":"2016","unstructured":"Lin S-H, Wang B-Y, Lin C-H, Chien P-J, Wu Y-F, Ko J-L, et al. Chidamide alleviates TGF-\u03b2-induced epithelial\u2013mesenchymal transition in lung cancer cell lines. Mol Biol Rep. 2016;43:687\u201395.","journal-title":"Mol Biol Rep"},{"key":"2254_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/onco.13609","volume":"26","author":"MM Cook","year":"2021","unstructured":"Cook MM, Al Rabadi L, Kaempf AJ, Saraceni MM, Savin MA, Mitri ZI. Everolimus plus exemestane treatment in patients with metastatic hormone receptor-positive breast cancer previously treated with CDK4\/6 inhibitor therapy. Oncologist. 2021;26:101\u20136.","journal-title":"Oncologist"},{"key":"2254_CR12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(21)00034-6","volume":"22","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021;22:489\u201398.","journal-title":"Lancet Oncol"},{"key":"2254_CR13","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388:2058\u201370.","journal-title":"N Engl J Med"},{"key":"2254_CR14","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32:1475\u201395.","journal-title":"Ann Oncol"},{"key":"2254_CR15","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1016\/j.apsb.2023.02.001","volume":"13","author":"B Xu","year":"2023","unstructured":"Xu B, Zhang Q, Hu X, Li Q, Sun T, Li W, et al. Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. Acta Pharm Sin B. 2023;13:2250\u20138.","journal-title":"Acta Pharm Sin B"},{"key":"2254_CR16","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00018-019-03281-4","volume":"77","author":"J Zhang","year":"2020","unstructured":"Zhang J, Wang Q, Wang Q, Cao J, Sun J, Zhu Z. Mechanisms of resistance to estrogen receptor modulators in ER+\/HER2- advanced breast cancer. Cell Mol Life Sci. 2020;77:559\u201372.","journal-title":"Cell Mol Life Sci"},{"key":"2254_CR17","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1210\/me.2016-1072","volume":"30","author":"S L\u00e9gar\u00e9","year":"2016","unstructured":"L\u00e9gar\u00e9 S, Basik M. Minireview: the link between ER\u03b1 corepressors and histone deacetylases in Tamoxifen resistance in breast cancer. Molecular Endocrinology (Baltimore, Md). 2016;30:965\u201376.","journal-title":"Molecular Endocrinology (Baltimore, Md)"},{"key":"2254_CR18","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1158\/0008-5472.CAN-10-2458","volume":"71","author":"GJ Sabnis","year":"2011","unstructured":"Sabnis GJ, Goloubeva O, Chumsri S, Nguyen N, Sukumar S, Brodie AMH. Functional activation of the estrogen receptor-\u03b1 and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res. 2011;71:1893\u2013903.","journal-title":"Cancer Res"},{"key":"2254_CR19","doi-asserted-by":"publisher","DOI":"10.21037\/atm-23-1913","volume":"11","author":"J Suo","year":"2023","unstructured":"Suo J, Zhu K, Zhuang C, Zhong X, Bravaccini S, Maltoni R, et al. Efficacy and safety of tucidinostat in patients with advanced hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: real-world insights. Ann Transl Med. 2023;11:409.","journal-title":"Ann Transl Med"},{"key":"2254_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01462-3","volume":"23","author":"JO Brett","year":"2021","unstructured":"Brett JO, Spring LM, Bardia A, Wander SA. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 2021;23:85.","journal-title":"Breast Cancer Res"},{"key":"2254_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc1779","volume":"6","author":"S Minucci","year":"2006","unstructured":"Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6:38\u201351.","journal-title":"Nat Rev Cancer"},{"key":"2254_CR22","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925\u201336.","journal-title":"N Engl J Med"},{"key":"2254_CR23","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738\u201348.","journal-title":"N Engl J Med"},{"key":"2254_CR24","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","volume":"19","author":"D Tripathy","year":"2018","unstructured":"Tripathy D, Im S-A, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19:904\u201315.","journal-title":"Lancet Oncol"},{"key":"2254_CR25","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge","year":"2017","unstructured":"Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35:2875\u201384.","journal-title":"J Clin Oncol"},{"key":"2254_CR26","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/s41591-021-01562-9","volume":"27","author":"B Xu","year":"2021","unstructured":"Xu B, Zhang Q, Zhang P, Hu X, Li W, Tong Z, et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat Med. 2021;27:1904\u20139.","journal-title":"Nat Med"},{"key":"2254_CR27","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S1470-2045(23)00172-9","volume":"24","author":"P Zhang","year":"2023","unstructured":"Zhang P, Zhang Q, Tong Z, Sun T, Li W, Ouyang Q, et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2023;24:646\u201357.","journal-title":"Lancet Oncol"},{"key":"2254_CR28","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1200\/JCO.23.01940","volume":"42","author":"EL Mayer","year":"2024","unstructured":"Mayer EL, Ren Y, Wagle N, Mahtani R, Ma C, DeMichele A, et al. PACE: a randomized phase II study of fulvestrant, palbociclib, and avelumab after progression on cyclin-dependent Kinase 4\/6 inhibitor and aromatase inhibitor for hormone receptor\u2013positive\/human epidermal growth factor receptor\u2013negative metastatic breast cancer. J Clin Oncol. 2024;42:2050\u201360.","journal-title":"J Clin Oncol"},{"key":"2254_CR29","doi-asserted-by":"crossref","unstructured":"Kalinsky K, Bianchini G, Hamilton EP, Graff SL, Park KH, Jeselsohn R, et al. Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4\/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial. Journal of Clinical Oncology. 2024;42:LBA1001.","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1001"},{"key":"2254_CR30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1004","volume":"40","author":"K Kalinsky","year":"2022","unstructured":"Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Trivedi MS, Novik Y, et al. A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4\/6 inhibition (CDK 4\/6i) in patients (pts) with unresectable or hormone receptor\u2013positive (HR+), HER2-negative metastatic breast cancer (MBC): maintain trial. J Clin Oncol. 2022;40:LBA1004.","journal-title":"J Clin Oncol"},{"key":"2254_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6762","volume":"13","author":"D Li","year":"2024","unstructured":"Li D, Jin Y, Lin M, Zeng C, Guo Q, Liu Y, et al. Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world multicenter study. Cancer Med. 2024;13:e6762.","journal-title":"Cancer Med"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02254-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02254-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02254-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:55:36Z","timestamp":1776056136000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02254-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2254"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02254-3","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol and informed consent form were approved (CZLS2021028-A) by the Chongqing University Cancer Hospital. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"A signed informed consent was obtained from each participant. The informed consent is available upon request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}